Profil
Helen Ho is Chief Business & Strategy Officer at Parabilis Medicines, Inc. since 2026.
Former roles include Chief Business Officer at Blueprint Medicines Corp.
from 2022 to 2025, Director-Business Development & Operations at Agios Pharmaceuticals, Inc., and Vice President & Head-Corporate Development at TCR² Therapeutics, Inc. Education includes a doctorate from Yale University and an undergraduate degree from the University of California Los Angeles Graduate School.
Aktiva positioner av Helen Ho
| Företag | Position | Start |
|---|---|---|
| PARABILIS MEDICINES, INC. | Företagsledare/Principal | 2026-04-10 |
Tidigare kända positioner av Helen Ho
| Företag | Position | Slut |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Företagsledare/Principal | 2025-01-01 |
| AGIOS PHARMACEUTICALS, INC. | Företagsledare/Principal | - |
| TCR2 THERAPEUTICS INC. | Företagsledare/Principal | - |
Helen Hos utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 6 |
|---|---|
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Parabilis Medicines
Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Health Technology |
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
University of California Los Angeles Graduate School
University of California Los Angeles Graduate School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















